Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics

Vascular Biogenics Ltd. - Ordinary Shares (VBLT): $0.15

0.00 (-0.26%)

POWR Rating

Component Grades













VBLT Stock Summary

  • VBLT has a higher market value than only 3.41% of US stocks; more precisely, its current market capitalization is $10,671,768.
  • With a year-over-year growth in debt of -69.44%, VASCULAR BIOGENICS LTD's debt growth rate surpasses just 3.25% of about US stocks.
  • The volatility of VASCULAR BIOGENICS LTD's share price is greater than that of 98.27% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VASCULAR BIOGENICS LTD are ATNM, BLDP, IMGN, TMBR, and VSTM.
  • VBLT's SEC filings can be seen here. And to visit VASCULAR BIOGENICS LTD's official web site, go to

VBLT Valuation Summary

  • In comparison to the median Healthcare stock, VBLT's EV/EBIT ratio is 97.67% lower, now standing at 0.2.
  • Over the past 99 months, VBLT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for VBLT.

Stock Date P/S P/B P/E EV/EBIT
VBLT 2022-11-25 12.1 0.4 -0.3 0.2
VBLT 2022-11-23 12.4 0.4 -0.3 0.2
VBLT 2022-11-22 11.4 0.4 -0.3 0.2
VBLT 2022-11-21 10.9 0.4 -0.2 0.2
VBLT 2022-11-18 10.7 0.4 -0.2 0.2
VBLT 2022-11-17 10.8 0.4 -0.2 0.2

VBLT Growth Metrics

    Its 4 year price growth rate is now at -78.76%.
  • The 3 year net cashflow from operations growth rate now stands at -82.46%.
  • Its 2 year net income to common stockholders growth rate is now at -64.75%.
Over the past 52 months, VBLT's revenue has gone down $13,353,000.

The table below shows VBLT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.854 -31.508 -38.139
2022-06-30 0.572 -31.563 -35.471
2022-03-31 0.696 -27.27 -34.065
2021-12-31 0.768 -24.984 -29.92
2021-09-30 0.777 -25.545 -28.07
2021-06-30 0.771 -22.289 -27.345

VBLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VBLT has a Quality Grade of C, ranking ahead of 42.6% of graded US stocks.
  • VBLT's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • ISEE, SRNE, and CNCE are the stocks whose asset turnover ratios are most correlated with VBLT.

The table below shows VBLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.015 0.403 -1.059
2021-03-31 0.016 0.418 -0.951
2020-12-31 0.020 0.573 -0.863
2020-09-30 0.018 0.724 -0.741
2020-06-30 0.015 0.742 -0.740
2020-03-31 0.014 0.749 -0.628

VBLT Price Target

For more insight on analysts targets of VBLT, see our VBLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.38 Average Broker Recommendation 1.38 (Strong Buy)

VBLT Stock Price Chart Interactive Chart >

Price chart for VBLT

VBLT Price/Volume Stats

Current price $0.15 52-week high $2.29
Prev. close $0.15 52-week low $0.11
Day low $0.15 Volume 1,557,900
Day high $0.16 Avg. volume 1,452,327
50-day MA $0.14 Dividend yield N/A
200-day MA $0.90 Market Cap 10.61M

Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio

Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.

VBLT Latest News Stream

Event/Time News Detail
Loading, please wait...

VBLT Latest Social Stream

Loading social stream, please wait...

View Full VBLT Social Stream

Latest VBLT News From Around the Web

Below are the latest news stories about VASCULAR BIOGENICS LTD that investors may wish to consider to help them evaluate VBLT as an investment opportunity.

H.C. Wainwright Reaffirms Their Hold Rating on Vascular Biogenics (VBLT)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Hold rating on Vascular Biogenics (VBLT - Research Report). The company's shares closed yesterday at $0.13.According to TipRanks, Ramakanth is an analyst with an average return of -16.4% and a 27.74% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, Innate Pharma, and EDAP TMS.The word on The Street in general, suggests a Hold analyst consensus rating for Vascular Biogenics.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $2.38 and a one-year low of $0.11. Currently, Vascular Biogenics has an average volume of 1.59M.

Carrie Williams on TipRanks | November 18, 2022

Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -9.09% and 220.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 15, 2022

VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Continued progress on previously announced strategic process to maximize shareholder valueTEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update. “VBL’s management team and board continue to make good progress on the evaluation of strategic

Yahoo | November 14, 2022

OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.

Yahoo | September 2, 2022

Read More 'VBLT' Stories Here

VBLT Price Returns

1-mo 20.00%
3-mo N/A
6-mo -90.20%
1-year -92.99%
3-year -88.00%
5-year -97.66%
YTD -92.39%
2021 4.23%
2020 57.50%
2019 23.71%
2018 -86.34%
2017 46.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7341 seconds.